Nabi announces positive phase 1 results for two bacterial infection vaccines

By Lisa Kerner

Erie, Pa., Feb. 7 - Nabi Biopharmaceuticals said data from phase 1 studies of its S. epidermidis PS-1 vaccine and its S. aureus Type 336 vaccine demonstrated that escalating doses of the vaccines were well tolerated and resulted in significant dose-related increases in levels of antibodies against S. epidermidis PS-1 and S. aureus Type 336.

Together S. epidermidis and S. aureus bacteria account for two-thirds of health care-associated infections reported annually, according to a company news release.

Both phase 1 studies evaluated the safety and immune response of these vaccines in healthy volunteers.

The S. epidermidis PS-I phase 1 study was a double-blinded, dose-escalating, placebo-controlled study of the vaccine in 36 patients at three different dosage levels.

The Type 336 phase 1 study was a double-blinded, dose-escalating, placebo-controlled study of the vaccine in 48 patients at four different dosage levels.

Nabi said it plans to advance the two vaccines into a phase 2 clinical trial, designed as a proof-of-concept study, in the first half of 2007.

The company said that by 2008, the market for new hospital anti-bacterial products will reach an estimated $10.1 billion.

Nabi is a biopharmaceutical company with a focus on gram-positive bacterial infections, hepatitis, kidney disease and nicotine addiction. The company is based in Rockville, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.